Insilico Medicine: AI for Drug Discovery, Biomarker Development and Ageing Research

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, offices in 6 countries. The company was the first to apply the generative adversarial networks (GANs) and reinforcement learning (RL) to generate new molecular structures with the specified parameters in 2015. In addition to collaborating with large pharmaceutical companies, Insilico Medicine is also pursuing internal drug discovery programs in different types of diseases and anti-aging fields. Recently, Insilico Medicine published a paper in Nature Biotechnology, hit found within 46 days, and secured $37 million in series B funding, led by Qiming Venture Partners.   website：http://insilico.com/

Next Generation AI Services - End to End Solutions for Pharmaceutical Industry

• Target Identification Pipelines
• Generation of Novel Small Molecule Leads
• Predictors of Clinical Trial Outcomes

【Award Records】

• 2017 NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact.
• 2018 Insilico Medicine was named one of the global top 100 AI companies by CB Insights
• 2018 Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award